Atara Biotherapeutics Stock Price Forecast. Should You Buy ATRA?

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

ATRA Forecast — Price Target — Prediction for 2027

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

ATRA Stock Pops As Traders Zero In On Volatile Spike

ATRA Stock Surges As Traders Pile Into Biotech Momentum

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx